BioSpace News Archive

Tampa General Hospital (TGH) and USF Health Morsani College of Medicine Interventional Cardiologists reached multiple milestones this week in being the first in Florida and second in the nation to use a newly developed heart implant designed to replace the tricuspid valve and offer an option to patients who do not meet the criteria for open heart surgery.

Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that the U.S. Food and Drug Administration (FDA) has approved ZTALMY® (ganaxolone) oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder (CDD).

Jasper Therapeutics, Inc. (NASDAQ: JSPR), a biotechnology company focused on transforming the field of hematopoietic stem cell therapies, today announced results for the fiscal year ended December 31, 2021, and provided a business update.

Janux Therapeutics, Inc. today reported financial results for the fourth quarter and full year ended December 31, 2021 and provided a business update.

Viracta Therapeutics, Inc. today announced that the Compensation Committee of Viracta’s Board of Directors approved the grant of non-qualified stock options to a new non-executive employee to purchase an aggregate of 200,000 shares of common stock.

Galapagos issued 95,500 new ordinary shares on 18 March 2022, for a total capital increase of €2,159,600.00.

BioLife Solutions, Inc. announced today that it has received a notice (“Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) as a result of its failure to timely file its Annual Report on Form 10-K for the year ended December 31, 2021 (the “Form 10-K”).

Akumin Inc. announced the departure of its President and Co-Chief Executive Officer, Rhonda Longmore-Grund, effective , following the decision by its board of directors to not continue with the co-CEO arrangement.

Arcturus Therapeutics Holdings Inc. announced that the Compensation Committee of the Company’s Board of Directors and the Company’s Board of Directors approved inducement grants of stock options to purchase an aggregate of 20,000 shares of Arcturus’ common stock to two newly-hired employee.

Bristol Myers Squibb (NYSE: BMY) today announced that OpdualagTM (nivolumab and relatlimab-rmbw), a new, first-in-class, fixed-dose combination of nivolumab and relatlimab, administered as a single intravenous infusion, was approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult and pediatric patients 12 years of age or older with unresectable or metastatic melanoma.